Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.75 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839255 | 0.98 | TBXAS1 (0.79) | TBXAS1HMOX1NOS1 | |
| Bromide SCHEMBL10851882 | 0.98 | TBXAS1 (0.72) | TBXAS1HMOX1NOS1 | |
| SCHEMBL28281551 | 0.98 | TBXAS1 (0.79) | TBXAS1HMOX1NOS1 | |
| SCHEMBL28280378 | 0.98 | TBXAS1 (0.79) | TBXAS1HMOX1NOS1 | |
| Bromide SCHEMBL28914614 | 0.96 | TBXAS1 (0.76) | TBXAS1HMOX1NOS1 | |
| Bromide SCHEMBL28915325 | 0.96 | TBXAS1 (0.76) | TBXAS1HMOX1NOS1 | |
| SCHEMBL1052113 | 0.93 | — | — | |
| Bromide SCHEMBL6635203 | 0.91 | TBXAS1 (0.68) | TBXAS1HMOX1NOS1 | |
| SCHEMBL937596 | 0.89 | TBXAS1 (0.95) | TBXAS1HMOX1 | |
| Acetic Acid SCHEMBL9711505 | 0.88 | TBXAS1 (0.61) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1566111-A | Preparation method of cyclic carbonate | LANZHOU CHEM PHYS INST (CN) | 2005-01-19 | — | — | CN | claimed |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
| CN-109336944-A | Celastrol imdazole derivatives and preparation method thereof and purposes | 中国药科大学 | 2019-02-15 | — | — | CN | disclosed |
| CN-109294143-A | A kind of cyclodextrin-polymeric ionic liquid functionalization graphene composite material and preparation method and application | 辽宁大学 | 2019-02-01 | — | — | CN | disclosed |
| CN-108465488-A | N- heterocycle carbines ruthenium catalyst containing imidazolium ionic liquid group and its application | 天津斯瑞吉高新科技研究院有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-106925351-B | N-heterocyclic carbene ruthenium catalyst containing imidazolium salt ionic liquid group and preparation method thereof | 天津斯瑞吉高新科技研究院有限公司 | 2018-02-23 | — | — | CN | disclosed |
| US-20170352818-A1 | LIGHT EMITTING ELECTROCHEMICAL CELLS AND COMPOUNDS | UNIV COURT UNIV ST ANDREWS (GB) | 2017-12-07 | — | — | US | disclosed |
| CN-105110406-B | Application of the ion liquid functionalization silica gel in Phenol for Waste Water pollutant is removed | 河南师范大学 | 2017-11-24 | — | — | CN | disclosed |
| CN-107353252-A | A kind of ionic liquid with carboxylic acid and its preparation method and application | 辽宁大学 | 2017-11-17 | — | — | CN | disclosed |
| CN-1566111-A | Preparation method of cyclic carbonate | LANZHOU CHEM PHYS INST (CN) | 2005-01-19 | — | — | CN | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
| US-20030187240-A1 | 2' -modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6531584-B1 | Nuclease resistant oligonucleotide analogs; DNA or RNA modulation; diagnosis, thearpy of viral diseases | ISIS PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030004325-A1 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6399754-B1 | CONTAINING SULFOPHOSPHATE GROUP | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6005087-A | NUCLEASE RESISTANT OLIGONUCLEOTIDES WHICH ARE USEFUL AS THERAPEUTICS, DIAGNOSTICS, AND RESEARCH REAGENTS FOR VARIOUS VIRAL DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859221-A | HYBRID DNA, RNA; NUCLEASE RESISTANT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5089392-A | Medical diagnosis | THE UNITED STATES OF AMERICA AS REPRESENTED BY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | CNR2, CNR1, GPR18 | TBXAS1 1013/4885HMOX1 491/4885NOS1 1615/4885 |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | TBXAS1 1337/4885HMOX1 547/4885NOS1 1819/4885 |
| US-20170352818-A1 | LIGHT EMITTING ELECTROCHEMICAL CELLS AND COMPOUNDS | MAP1LC3C, TRPC1, HLCS | TBXAS1 2670/4885HMOX1 3223/4885NOS1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.